NCT05418309Unknown2 期
An Open Label, Single-arm, Phase 2 Study of Tislelizumab Combined With Nab-Paclitaxel for Patients With High-Risk Non-Muscle-Invasive Urothelial Bladder Carcinoma Which is Not Completely Resectable: a Multi-center Study
Tianjin Medical University Second Hospital1 个研究点 分布在 1 个国家目标入组 63 人开始时间: 2021年12月27日最近更新:
适应症
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 发起方
- 入组人数
- 63
- 试验地点
- 1
- 主要终点
- Complete Response (CR) Rate for tilelizumab combined with nab-paclitaxel
研究概览
简要总结
This is a phase II study to determine the safety and efficacy of tislelizumab when given in combination with nab-paclitaxel as treatment for patients with high-risk non-muscle-invasive bladder cancer (HR NMIBC) which is not completely resectable. Patients will receive treatment with tislelizumab in combination with nab-paclitaxel every 3 weeks for 4 treatment cycles over 12 weeks followed by transurethral resection biopsy.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Willing and able to provide written informed consent;
- •Ability to comply with the protocol;
- •Age ≥ 18 years;
- •High-risk non-muscle-invasive urothelial carcinoma or high-risk non-muscle-invasive urothelial carcinoma as the main pathological component > 50%, difined as following:
- •a. T1 b. High-grade Ta c.Carcinoma in situ(CIS);
- •Multi-point biopsy of bladder shows there are more than 2 section and over 3 points of pathological specimens are diagnosed as above, meanwhile, the tumor has to be diagnosed as not completely resectable by at least 2 senior urologist;
- •Eastern Cooperative Oncology Group (ECOG) Performance Status of 0-2;
- •Agreed to provide tissue examination samples (for detection of PD-L1 expression, tumor mutation load, IHC, detection of DNA and RNA, etc;)
- •Organ function level must meet the following requirements:
- •Hematological indexes: neutrophil count >= 1.5x10^9/L, platelet count >= 80x10^9/L, hemoglobin >= 6.0 g/dl (can be maintained by blood transfusion);
- •Liver function: total bilirubin <=1.5 ULN, alanine aminotransferase and aspartate aminotransferase <=2.5 ULN;
- •The subjects volunteered to join the study, signed informed consent, and had good compliance with follow-up;
排除标准
- •Receive live attenuated vaccine within 4 weeks before treatment or during the study period;
- •Active, known or suspected autoimmune diseases;
- •History of primary immunodeficiency;
- •Known history of allogeneic organ transplantation and allogeneic hematopoietic stem cell transplantation;
- •Pregnant or lactating female patients;
- •Untreated acute or chronic active hepatitis B or hepatitis C infection. Under the condition of monitoring the virus copy number of patients receiving antiviral treatment, doctors can judge whether they are in line with the patients' individual conditions;
- •Prior use of immunosuppressive drugs within 4 weeks prior to the start of treatment, excluding nasal and inhaled corticosteroids or physiological doses of systemic steroids (i.e. not more than 10 mg / day prednisolone or other corticosteroids with the same physiological dose);
- •Known or suspected allergy to tislelizumab and albumin paclitaxel;
- •Have a clear history of active tuberculosis;
- •Received PD-1 / PD-L1 / CTLA-4 antibody or other immunotherapy in the past;
- •Participating in other clinical researchers;
- •Men with reproductive capacity or women who are likely to become pregnant do not take reliable contraceptive measures;
- •Uncontrolled concurrent diseases, including but not limited to:
- •HIV infected (HIV antibody positive);
- •Severe infection in active stage or poorly controlled;
- •Evidence of serious or uncontrollable systemic diseases (such as severe mental, neurological, epilepsy or dementia, unstable or uncompensated respiratory, cardiovascular, liver or kidney diseases, uncontrolled hypertension [i.e. hypertension greater than or equal to CTCAE grade 2 after drug treatment]);
- •Patients with active bleeding or new thrombotic disease
研究组 & 干预措施
Tislelizumab and Nab-Paclitaxel
Experimental
Tislelizumab 200mg IV on day 1 in combination with nab-paclitaxel 200mg IV on day 2 every 3 weeks for 3 or 4 cycles followed by transurethral resection biopsy.
干预措施: Tislelizumab Nab paclitaxel (Drug)
结局指标
主要结局
Complete Response (CR) Rate for tilelizumab combined with nab-paclitaxel
时间窗: At the time of transurethral resection biopsy (within 9 or 12 weeks of the first dose of tislelizumab)
次要结局
- Cystectomy-Free Survival (CFS)(up to 3 years)
- Duration of Response (DOR)(up to 3 years)
- Number of adverse events and severity by grade (CTCAE) Number of adverse events and severity by grade (CTCAE)(12 weeks of treatment plus 30 days for toxicity followup)
研究者
研究点 (1)
Loading locations...
相似试验
Unknown
2 期
Tilelizumab Combined With Nab-Paclitaxel for High-Risk Non-Muscle-Invasive Urothelial Bladder Carcinoma Which is Not Completely ResectableHigh-RiskNon-Muscle Invasive Bladder Urothelial CarcinomaNCT04730232Tianjin Medical University Second Hospital63
进行中（未招募）
2 期
Perioperative Tislelizumab Combined With Nab-Paclitaxel for Muscle-invasive Urothelial Bladder CarcinomaMuscle Invasive Bladder CancerUrothelial CarcinomaNCT04730219Tianjin Medical University Second Hospital48
进行中（未招募）
2 期
Phase II Study of Tislelizumab Combined With Cetuximab and Irinotecan in the Treatment of Recurrent, Refractory mCRCColorectal NeoplasmsNCT05143099Shanghai Zhongshan Hospital35
招募中
2 期
Tislelizumab Plus Lenvatinib in Stage III-IV RCCAdvanced Kidney CancerNCT05485883Tianjin Medical University Second Hospital20
Unknown
1 期
Study of Chemotherapy and PD-1 Inhibitor Combination With Anti-angiogenesis to Treat Elderly Lung CancerNon-Small Cell Lung CancerNCT05273814Tianjin Medical University Cancer Institute and Hospital30